Arcturus Therapeutics is actively engaged in partnering discussions. Please contact BD@ArcturusRx.com regarding any business development opportunities.
News & Events
May 8, 2013
Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board
READ MOREJune 3, 2013
RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round
READ MOREAugust 14, 2013
Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
READ MOREOctober 21, 2013
GenomeWeb Acturus Closes $5M Series A Round, Aims for Clinic in '15 with RNAi Drug
READ MOREOctober 21, 2013
RNAi firm raises $5M to develop and deliver drugs that turn off disease-causing genes
READ MOREOctober 21, 2013
Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
READ MOREOctober 21, 2013
Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
READ MOREOctober 28, 2013
Arcturus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., as Chief Business Officer
READ MOREJanuary 13, 2014
Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
READ MOREJanuary 13, 2014
Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
READ MOREJanuary 30, 2014
Arcturus Therapeutics to Present at the Keystone Symposia Conference on RNA Silencing
READ MOREFebruary 24, 2014
Arcturus Therapeutics to Present RNAi Data for Orphan Diseases Utilizing the LUNARTM Technology Platform at BIOCOM's Global Life Science Partnering Conference
READ MOREFebruary 27, 2014
Arcturus Releases Data Showing Potential of Delivery Technology for CRISPR Drugs
READ MOREMarch 10, 2014
Arcturus Therapeutics to Present at the BIO-Europe Spring Partnering Conference
READ MOREMarch 27, 2014
Arcturus Therapeutics to Present at the BioCentury Future Leaders in the Biotech Industry Conference
READ MOREApril 7, 2014
Arcturus Therapeutics to Present at the 13th Annual Needham Healthcare Conference
READ MOREMay 6, 2014
Arcturus Therapeutics Appoints Robert Baltera and Stuart Collinson, Ph.D. to its Board of Directors
READ MOREMay 13, 2014
Arcturus Therapeutics Announces Allele-Specific Silencing Technology at IBC’s 16th Annual TIDES Conference
READ MOREOctober 13, 2014
Arcturus Therapeutics to Present Gene Knockdown Data in Non-Human Primates, Showing up to 94% Reduction in Gene Expression with a Single Low Dose
READ MOREOctober 16, 2014
Arcturus Touts Dosing, Specificity of ATTR Drugs as They Move Toward Clinic
READ MORENovember 10, 2014
Arcturus Therapeutics Presents Preclinical Messenger RNA Data in Non-Human Primates at the 2nd International mRNA Health Conference
READ MOREDecember 1, 2014
Arcturus Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
READ MOREDecember 3, 2014
Arcturus Therapeutics to Present at the Genetic Rx Boston Biotech Conference
READ MOREDecember 9, 2014
Arcturus Therapeutics Announces the Appointment of Michael R. Hodges, M.D. to the Scientific Advisory Board
READ MOREJanuary 7, 2015
Arcturus Therapeutics to Present Messenger RNA Pipeline at the 33rd Annual J.P. Morgan Healthcare Conference and the 7th Annual Biotech Showcase
READ MOREJanuary 9, 2015
Precision NanoSystems and Arcturus Therapeutics Announce a Partnership for the Manufacture of RNA Medicines
READ MOREJune 11, 2015
Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications
READ MOREOctober 29, 2015
Ultragenyx Pharmaceutical and Arcturus Therapeutics Announce a Research Collaboration and License Agreement to Develop RNA Therapeutics for Rare Diseases
READ MORENovember 3, 2015
Arcturus Therapeutics Announces the Appointment of Drew Weissman M.D., Ph.D. to the Scientific Advisory Board
READ MOREMarch 16, 2016
Arcturus Therapeutics Receives Intent to Grant Notice from the European Patent Office for their Unlocked Nucleomonomer Agent (UNA) Technology
READ MOREJune 1, 2016
Arcturus Therapeutics To Present At 2016 BIO International Convention in San Francisco
READ MOREOctober 3, 2016
Arcturus Therapeutics to Report Identification of LUNAR-HBV, a Potent Combination of Three UNA Oligomers Targeting All Hepatitis B Virus Genotypes at the AASLD Liver Meeting® 2016
READ MOREDecember 6, 2016
Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA–based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)
READ MOREFebruary 9, 2017
Arcturus Therapeutics to Present at the 19th Annual BIO CEO & Investor Conference
READ MOREFebruary 13, 2017
Arcturus Therapeutics to Present at the 19th Annual Bio CEO and Investor Conference in NY
READ MOREFebruary 15, 2017
Collaboration between Salk institute (Verma lab) and Arcturus Therapeutics Inc. to treat hemophilia B in mice
READ MOREFebruary 15, 2017
PNAS Publication on Arcturus and Salk--Systemic delivery of factor IX messenger RNA for protein replacement therapy
READ MOREFebruary 24, 2017
Arcturus To Attend 8th Annual SBP Rare Disease Day Symposium: Alagille Syndrome - New Research, New Hope
READ MOREMarch 3, 2017
Arcturus To present at UCSF Rare Disease Symposium: “A New Era of Nucleic Acid Therapeutics to Treat Orphan Diseases”.
READ MOREMarch 7, 2017
BioCentury featuring Arcturus Therapeutics in an article called Getting the Message
READ MOREMarch 30, 2017
Arcturus to present at RNA & Oligonucleotide Therapeutics-Cold Spring Harbor Labratory
READ MOREApril 3, 2017
Arcturus to present at the ACS 253rd National Meeting, on Potent delivery of LUNAR™ nanoparticles containing synthetic mRNA for therapeutic protein expression
READ MOREApril 6, 2017
Melinda Richter, Head of Johnson & Johnson Innovation JLABS, highlighting Arcturus in the Nature Reviews Drug Discovery
READ MOREApril 10, 2017
Arcturus Therapeutics is Selected by Ernst and Young as Semifinalists for the Entrepreneur Of The Year® 2017 Award in San Diego
READ MOREApril 10, 2017
Arcturus Therapeutics is Selected by Ernst and Young as Semifinalists for the Entrepreneur Of The Year® 2017 Award in San Diego
READ MOREApril 10, 2017
Arcturus Therapeutics is Selected by Ernst and Young as Semifinalists for the Entrepreneur Of The Year® 2017 Award in San Diego
READ MOREApril 29, 2017
Arcturus Therapeutics to Present at the TIDES--Oligonucleotides and Peptide Therapeutics, on Unlocked Nucleomonomer Agent (UNA) Oligomer System, Challenges and Opportunities
READ MOREMay 15, 2017
Ernst & Young Selected Arcturus as the Finalists for the Entrepreneur Of The Year 2017 Award® in San Diego
READ MOREJune 1, 2017
GEN News Featuring Arcturus Therapeutics on its cover page--in Better Targeting, Delivery of RNAi Therapies
READ MOREJune 16, 2017
Arcturus Therapeutics to Present at 2017 Bio International Convention (Mon June 19th)
READ MOREJuly 13, 2017
Arcturus Therapeutics Inc. is Listed in the Key Players List; Involved in Non Alcoholic Steatohepatitis Pipeline (NASH)
READ MOREAugust 23, 2017
Pictures by Ernst and Young (Finalists for the Entrepreneur Of The Year 2017 Award® in San Diego)
READ MOREMay 30, 2017
Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation Therapeutics to Advance a Novel LUNAR-Formulated mRNA CFTR Therapeutic
READ MOREOctober 6, 2017
Arcturus Therapeutics, Inc. to Present at the Chardan Gene Therapy Conference
READ MOREOctober 19, 2017
Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines
READ MOREOctober 30, 2017
Arcturus Therapeutics to Present at the 5th International mRNA Health Conference on Nov 1st
READ MOREOctober 30, 2017
Arcturus Therapeutics to Present at the 2017 North American Cystic Fibrosis Conference on Nov 2nd
READ MORENovember 2, 2017
Arcturus Therapeutics to Host Key Opinion Leader Call on Advances in Delivery of Nucleic Acid Medicines on Tuesday, November 7
READ MORENovember 16, 2017
Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market
READ MORENovember 16, 2017
Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market
READ MOREDecember 6, 2017
Arcturus Therapeutics Ltd., to Present at Genetic Rx Conference at Harvard Medical School (Dec 7th), in a Panel Discussion Called “Next Generation RNA Technologies”
READ MOREJanuary 5, 2018
Johnson & Johnson Innovation Champions Leading Edge Science with 15 New Collaborations with Potential to Impact Patients' Lives
READ MOREMay 29, 2018
Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne
READ MOREMay 31, 2018
Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO
READ MOREJune 18, 2018
Arcturus Therapeutics to Present at the JMP Securities Life Sciences Conference
READ MOREJuly 9, 2018
Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
READ MOREJuly 20, 2018
Arcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Held on August 24, 2018
READ MOREJuly 23, 2018
Arcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeutics
READ MOREAugust 28, 2018
Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer
READ MOREAugust 29, 2018
Arcturus Therapeutics Announces Appointment of Ernst & Young LLP as the Company’s Independent Auditor
READ MOREOctober 1, 2018
Arcturus Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
READ MORENovember 5, 2018
Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility
READ MORENovember 7, 2018
Arcturus Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results
READ MOREJanuary 2, 2019
Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency
READ MOREFebruary 11, 2019
Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency
READ MOREMarch 18, 2019
Arcturus Therapeutics Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Results
READ MOREMay 13, 2019
Arcturus Therapeutics Announces First Quarter Financial Results and Provides a Corporate Update
READ MOREMay 20, 2019
Arcturus Therapeutics Presenting Data for ARCT-810 and the Arcturus mRNA + LUNAR® Technology Platform at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics
READ MOREJune 13, 2019
Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation
READ MOREJune 19, 2019
Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases
READ MOREJune 27, 2019
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency
READ MOREJuly 10, 2019
Arcturus Therapeutics to Participate in Two Panels at the ROTH RNA Revolution Conference
READ MOREAugust 1, 2019
Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis Patients
READ MOREAugust 1, 2019
Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock
READ MOREAugust 2, 2019
Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock
READ MOREAugust 15, 2019
Arcturus Therapeutics Announces Second Quarter Financial Results and Provides a Corporate Update
READ MORESeptember 23, 2019
Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors
READ MORESeptember 26, 2019
Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock
READ MORENovember 7, 2019
Arcturus Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
READ MOREJanuary 8, 2020
Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer
READ MOREFebruary 25, 2020
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11
READ MOREMarch 4, 2020
Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology
READ MOREMarch 11, 2020
Arcturus Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results
READ MOREMarch 27, 2020
Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System
READ MOREApril 9, 2020
Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine
READ MOREApril 13, 2020
Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency
READ MOREApril 16, 2020
Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock
READ MOREApril 20, 2020
Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology
READ MOREApril 21, 2020
Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
READ MOREApril 27, 2020
Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate
READ MOREMay 4, 2020
Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine
READ MOREMay 5, 2020
Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020
READ MOREMay 7, 2020
Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update
READ MOREMay 8, 2020
Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)
READ MOREMay 21, 2020
Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics
READ MOREJune 11, 2020
Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference
READ MOREJuly 1, 2020
Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board
READ MOREJuly 21, 2020
Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19
READ MOREJuly 23, 2020
Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19
READ MOREJuly 29, 2020
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock
READ MOREJuly 31, 2020
Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
READ MOREAugust 4, 2020
Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020
READ MOREAugust 10, 2020
Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update
READ MOREAugust 11, 2020
Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study
READ MOREAugust 18, 2020
Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health
READ MORESeptember 4, 2020
Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate
READ MORESeptember 8, 2020
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MOREOctober 1, 2020
Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference
READ MOREOctober 5, 2020
Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
READ MOREOctober 6, 2020
Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR®-COV19 (ARCT-021) vaccine candidate
READ MOREOctober 30, 2020
Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020
READ MORENovember 4, 2020
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORENovember 9, 2020
Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data
READ MOREDecember 7, 2020
Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency
READ MOREDecember 7, 2020
Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
READ MOREDecember 28, 2020
Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data
READ MOREDecember 30, 2020
Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease
READ MOREJanuary 4, 2021
Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States
READ MORE